Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to
Armata got special FDA approval to speed up testing a new germ-fighting medicine. This means the FDA thinks the medicine could really help sick patients with serious infections.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.